PUBLISHER: The Business Research Company | PRODUCT CODE: 1751076
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751076
Plant-based active pharmaceutical ingredients (APIs) are biologically active compounds derived from plants and are essential in the formulation of medications. These ingredients are important for their therapeutic effects, which can include treating, preventing, or managing various health conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main product types of plant-based active pharmaceutical ingredients (APIs) include alkaloids, glycosides, cannabinoids, flavonoids, terpenes and terpenoids, polyphenols, saponins, and others. Alkaloids are a diverse group of naturally occurring organic compounds, most of which contain basic nitrogen atoms. Plant-based active pharmaceutical ingredients (APIs) are sourced from various plant parts, including leaves, roots, bark, flowers, seeds, fruits, resins, gums, and other natural sources. These ingredients are distributed through various channels, such as online retailers, supermarkets and hypermarkets, specialty food stores, and foodservice providers, and are widely used across industries such as pharmaceuticals, nutraceuticals, herbal-based industries, and others.
The plant-based active pharmaceutical ingredients (API) market research report is one of a series of new reports from The Business Research Company that provides plant-based active pharmaceutical ingredients (API) market statistics, including plant-based active pharmaceutical ingredients (API) industry global market size, regional shares, competitors with a plant-based active pharmaceutical ingredients (API) market share, detailed plant-based active pharmaceutical ingredients (API) market segments, market trends and opportunities, and any further data you may need to thrive in the plant-based active pharmaceutical ingredients (API) industry. This plant-based active pharmaceutical ingredients (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The plant-based active pharmaceutical ingredients (API) market size has grown strongly in recent years. It will grow from$30.22 billion in 2024 to $32.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to factors such as the increasing use of traditional herbal medicine practices, a growing demand for natural remedies, the rise of early pharmaceutical formulations, the expanding global trade of medicinal herbs, and the increasing industrialization of botanical drugs.
The plant-based active pharmaceutical ingredients (API) market size is expected to see strong growth in the next few years. It will grow to$42.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to factors such as rising consumer preference for natural medicines, increasing investment in plant-based drug research, expanding applications in the treatment of chronic diseases, and growing collaborations between the pharmaceutical and botanical industries. Key trends during this period include AI-driven drug discovery, advanced plant tissue culture techniques, precision fermentation for plant-derived compounds, and green extraction methods aimed at sustainable production.
The rising consumer demand for natural and organic products is expected to drive the growth of the plant-based active pharmaceutical ingredients (API) market. Natural and organic products are those made from ingredients that are naturally sourced, minimally processed, and free from synthetic chemicals and genetically modified organisms (GMOs). This shift towards natural and organic products is largely due to increased health awareness and concerns over synthetic chemicals, with consumers becoming more conscious of the potential risks associated with synthetic ingredients. Plant-based active pharmaceutical ingredients (APIs) cater to this demand by providing effective, chemical-free medicinal benefits that align with the consumer preference for clean, safe, and sustainable healthcare options. For example, in May 2024, LETIS S.A., an Argentina-based organic certification authority, reported that organic food sales reached $61.67 billion in 2022, marking a 4.3% increase from the previous period. Additionally, other organic products contributed $5.906 billion, reflecting a 1.6% growth. As a result, the growing preference for natural and organic products is fueling the expansion of the plant-based active pharmaceutical ingredients (API) market.
Leading companies in the plant-based active pharmaceutical ingredients (API) market are focusing on developing innovative solutions such as plant-based squalene, which offer sustainable and ethical alternatives to traditional animal-derived sources. Plant-based squalene, derived from plants such as amaranth, olives, and sugarcane, serves as an ethical substitute for shark-derived squalene in pharmaceuticals, cosmetics, and vaccines. For instance, in October 2023, Evonik Industries AG, a Germany-based specialty chemicals company, launched PhytoSquene, the first GMP-quality, plant-based squalene sourced from amaranth oil. This innovation provides a sustainable alternative to shark-derived squalene, ensuring high purity, consistent batch quality, and compliance with European Pharmacopoeia (Ph. Eur.) standards. Squalene is an important ingredient in vaccine adjuvants, as it enhances the immune response. By offering a plant-based version, PhytoSquene addresses concerns about biodiversity, reduces reliance on animal-derived sources, and respects cultural and religious preferences.
In March 2024, Roquette Freres, a France-based provider of pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed sum. This acquisition aims to strengthen Roquette's position in the pharmaceutical excipients market by broadening its product portfolio and expertise in drug delivery. This move is expected to accelerate Roquette's growth in the health and nutrition sectors, positioning the company as a key partner for pharmaceutical companies. IFF Pharma Solutions, a US-based pharmaceutical company, specializes in offering plant-based active pharmaceutical ingredients.
Major players in the plant-based active pharmaceutical ingredients (API) market are Evonik Industries AG, Roquette Freres, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Koninklijke DSM NV, Alembic Pharmaceuticals Ltd, Seppic, Indena SpA, PAI Pharma, Centroflora Group, Alkaloids Corporation, SCL Lifesciences Ltd, Alchem International Pvt Ltd, AMGIS Lifescience Ltd, C2 Pharma, PhytoHealth Corp, Bright Green Corporation, Sichuan Xieli Pharmaceutical Co Ltd, Brains Bioceutical Corp, Organotechnie, and HimPharm.
North America was the largest region in the plant-based active pharmaceutical ingredients (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plant-based active pharmaceutical ingredients (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the plant-based active pharmaceutical ingredients (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The plant-based active pharmaceutical ingredients (API) market consists of sales of botanical extracts, plant-based steroids, essential oils, flavonoids, and botanical extracts. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Plant-Based Active Pharmaceutical Ingredients (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on plant-based active pharmaceutical ingredients (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for plant-based active pharmaceutical ingredients (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plant-based active pharmaceutical ingredients (api) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.